Key result
Metabolic syndrome in heart failure is linked to ~39% lower plasma adiponectin levels.
Why the study?
Is metabolic syndrome associated with altered plasma adiponectin concentrations in patients with heart failure?
Cross-Sectional (n=128)
No
Is metabolic syndrome associated with altered plasma adiponectin concentrations in patients with heart failure?
In patients with heart failure, the presence of metabolic syndrome is associated with significantly lower plasma adiponectin concentrations, which correlates with inflammation and abnormal diastolic function.
Answers are grounded in this paper and cite their sources.
Lower adiponectin in heart failure with metabolic syndrome should not change practice; leaves open its biomarker or therapeutic relevance.
PURPOSE: Plasma adiponectin concentrations are inversely related with metabolic syndrome (MetS), and MetS is associated with increased risk for heart failure (HF). However, the relationship between adiponectin and MetS in HF remains undetermined. Therefore, we tested whether MetS was associated with the degree of plasma adiponectin concentrations in HF patients. MATERIALS AND METHODS: One hundred twenty eight ambulatory HF patients with left ventricular ejection fraction of <50% (80 males, 61.8 ± 11.9 years old) were enrolled for this cross-sectional study. Echocardiographic measurements were performed, and plasma concentrations of adiponectin, lipoproteins, apolipoproteins (apoB, apoA1) and high sensitive C-reactive protein (hsCRP) were measured. RESULTS: Adiponectin concentrations in HF patients with MetS (n=43) were significantly lower than those without MetS (n=85) (9.7 ± 7.0 vs. 15.8 ± 10.9 μg/mL, p=0.001). Higher concentrations of apoB (p=0.017), apoB/A1 ratio (p<0.001), blood urea nitrogen (p=0.034), creatinine (p=0.003), and fasting insulin (p=0.004) were observed in HF patients with MetS compared with those without MetS. In HF patients with MetS, adiponectin concentrations were negatively correlated with hsCRP (r=-0.388, p=0.015) and positively correlated with the ratio of early mitral inflow velocity to early diastolic mitral annular velocity, E/E' (r=0.399, p=0.015). There was a significant trend towards decreased adiponectin concentrations with an increasing number of components of MetS (p for trend=0.012). CONCLUSION: Our study demonstrated that adiponectin concentrations decreased in HF patients with MetS, and that relationship between adiponectin, inflammation and abnormal diastolic function, possibly leading to the progression of HF.
No takes yet. Share an insight, caveat, or question.
Won et al. (2011) conducted a cross-sectional in Heart Failure (n=128). Metabolic Syndrome vs. Without Metabolic Syndrome was evaluated on Plasma adiponectin concentration (p=0.001). Plasma adiponectin concentrations were significantly lower in heart failure patients with metabolic syndrome compared to those without (9.7 vs. 15.8 µg/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: